CAC
BHVN

Cowen and Company’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cowen and Company’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,410
Closed -$542K – 629
2020
Q2 		$542K Buy
+7,410
New +$394K 0.09% 132
2020
Q1 		– Sell
-4,278
Closed -$233K – 646
2019
Q4 		$233K Sell
4,278
-22,222
-84% -$1.1M 0.02% 192
2019
Q3 		$1.11M Buy
+26,500
New +$1.12M 0.28% 63

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cowen and Company's BHVN Position: Q3 2020 in Review

Cowen and Company sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2020, closing a stake of 7,410 shares — an estimated $542K sold.

Cowen and Company first reported a position in BHVN in Q3 2019 and held it in 3 quarters. The position peaked at $1.11M in Q3 2019. 215 funds tracked by Wall St. Rank hold BHVN as of Q3 2020.

  • Cowen and Company reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2020 after selling out during the quarter.
  • Cowen and Company sold 7,410 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2020, an estimated $542K.
  • Cowen and Company first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 3 quarters.
  • Cowen and Company's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.11M in Q3 2019.
  • 215 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2020.

Based on Cowen and Company's 13F filing for Q3 2020, filed 3 Nov 2020.